CA2405247A1 - Antigenes de la tuberculose - Google Patents

Antigenes de la tuberculose Download PDF

Info

Publication number
CA2405247A1
CA2405247A1 CA002405247A CA2405247A CA2405247A1 CA 2405247 A1 CA2405247 A1 CA 2405247A1 CA 002405247 A CA002405247 A CA 002405247A CA 2405247 A CA2405247 A CA 2405247A CA 2405247 A1 CA2405247 A1 CA 2405247A1
Authority
CA
Canada
Prior art keywords
seq
ala
leu
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002405247A
Other languages
English (en)
Inventor
Else Marie Agger
Peter Andersen
Li Mei Meng Okkels
Karin Weldingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2405247A1 publication Critical patent/CA2405247A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne l'identification et la caractérisation de plusieurs nouvelles protéines et nouveaux fragments de protéines dérivées de <i>M. tuberculosis</i>. L'invention se rapporte aux polypeptides et aux fragments immunologiquement actifs de ceux-ci, aux gènes les codant, à des compositions immunologiques telles que des vaccins et à des réactifs pour tests cutanés contenant les polypeptides de l'invention.
CA002405247A 2000-04-19 2001-04-19 Antigenes de la tuberculose Abandoned CA2405247A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000666 2000-04-19
DKPA200000666 2000-04-19
DKPA200100283 2001-02-21
DKPA200100283 2001-02-21
PCT/DK2001/000276 WO2001079274A2 (fr) 2000-04-19 2001-04-19 Antigenes de la tuberculose

Publications (1)

Publication Number Publication Date
CA2405247A1 true CA2405247A1 (fr) 2001-10-25

Family

ID=26068815

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002405247A Abandoned CA2405247A1 (fr) 2000-04-19 2001-04-19 Antigenes de la tuberculose

Country Status (4)

Country Link
EP (1) EP1278769A2 (fr)
AU (1) AU2001250294A1 (fr)
CA (1) CA2405247A1 (fr)
WO (1) WO2001079274A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2621127A (en) * 2022-07-29 2024-02-07 Univ Johannesburg Witwatersrand Vaccine constructs comprising tuberculosis antigens

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1214088B1 (fr) 1999-05-04 2009-04-22 The University of Medicine and Dentistry of New Jersey Proteines exprimees par mycobacterium tuberculosis et non par bcg et employees en tant que vaccins et reactifs de diagnostic
WO2004006952A2 (fr) * 2002-07-13 2004-01-22 Statens Serum Institut Vaccin therapeutique contre la tuberculose
DE10251747A1 (de) * 2002-11-05 2004-05-19 Tuhh-Technologie-Gmbh Gentechnisch veränderte Penicillinamidase und Verfahren zu ihrer Herstellung
WO2004099771A1 (fr) * 2003-05-08 2004-11-18 Statens Serum Institut Methode de diagnostic immunologique de la tuberculose basee sur de nouveaux epitopes specifiques
WO2005061534A2 (fr) * 2003-12-23 2005-07-07 Statens Serum Institut Vaccins antituberculeux ameliores
ITRM20040091A1 (it) 2004-02-19 2004-05-19 Istituto Naz Per Le Malattie Test immunologico rapido per la diagnosi ed il monitoraggio dell'infezione tubercolare.
GB0406271D0 (en) * 2004-03-19 2004-04-21 Isis Innovation Diagnostic test
SG159555A1 (en) 2004-11-16 2010-03-30 Crucell Holland Bv Multivalent vaccines comprising recombinant viral vectors
JP5219808B2 (ja) 2005-06-23 2013-06-26 ステイテンス・セラム・インスティテュート 改良された結核ワクチン
US7993657B2 (en) 2005-07-26 2011-08-09 University Of Medicine And Dentistry Of New Jersey Antibody profiles characteristic of tuberculosis state
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
ES2741730T3 (es) 2008-05-19 2020-02-12 Advaxis Inc Sistema de administración doble para antígenos heterólogos que comprende una cepa de Listeria recombinante atenuada por la mutación de dal/dat y la deleción de ActA que comprende una molécula de ácido nucleico que codifica una proteína de fusión de listeriolisina O - antígeno prostático específico
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US20100015171A1 (en) 2008-07-15 2010-01-21 Statens Serum Institute Vaccines comprising tb 10.4
DK2421557T3 (en) 2009-04-24 2019-03-25 Statens Seruminstitut TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
WO2011063283A2 (fr) 2009-11-20 2011-05-26 Oregon Health & Science University Procédés destinés à détecter une infection par mycobacterium tuberculosis
EP2621527A4 (fr) 2010-10-01 2015-12-09 Univ Pennsylvania Utilisation de vecteurs de vaccin de listeria pour renverser l'insensibilité au vaccin chez des individus infectés par des parasites
EP2683400A4 (fr) 2011-03-11 2014-09-17 Advaxis Adjuvants à base de listeria
SG10201700392UA (en) 2012-03-12 2017-03-30 Advaxis Inc Suppressor cell function inhibition following listeria vaccine treatment
EP3555630B1 (fr) 2016-12-14 2023-05-31 Becton, Dickinson and Company Procédés et compositions permettant d'obtenir une évaluation de la tuberculose chez un sujet
CN111521819B (zh) * 2016-12-30 2023-06-20 首都医科大学附属北京胸科医院 结核分枝杆菌蛋白在制备诊断结核潜伏感染者和/或活动性肺结核产品中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972045A1 (fr) * 1997-04-02 2000-01-19 Statens Seruminstitut FRAGMENTS D'ACIDE NUCLEIQUE ET FRAGMENTS POLYPEPTIDIQUES DERIVES DE $i(M. TUBERCULOSIS)
US6555653B2 (en) * 1997-05-20 2003-04-29 Corixa Corporation Compounds for diagnosis of tuberculosis and methods for their use
US6613881B1 (en) * 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
EP1029053A1 (fr) * 1997-11-10 2000-08-23 Statens Seruminstitut Fragments d'acides nucleiques et fragments polypeptidiques derives de mycobacterium tuberculosis
EP1214088B1 (fr) * 1999-05-04 2009-04-22 The University of Medicine and Dentistry of New Jersey Proteines exprimees par mycobacterium tuberculosis et non par bcg et employees en tant que vaccins et reactifs de diagnostic
US7595383B1 (en) * 1999-05-04 2009-09-29 University Of Medicine And Dentistry Of New Jersey Secreted proteins of Mycobacterium tuberculosis and their use as vaccines and diagnostic reagents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2621127A (en) * 2022-07-29 2024-02-07 Univ Johannesburg Witwatersrand Vaccine constructs comprising tuberculosis antigens

Also Published As

Publication number Publication date
WO2001079274A8 (fr) 2004-04-29
WO2001079274B1 (fr) 2002-08-08
WO2001079274A2 (fr) 2001-10-25
WO2001079274A3 (fr) 2002-07-11
EP1278769A2 (fr) 2003-01-29
AU2001250294A1 (en) 2001-10-30

Similar Documents

Publication Publication Date Title
CA2405247A1 (fr) Antigenes de la tuberculose
EP1523331B1 (fr) Vaccin therapeutique contre la tuberculose
JP4759010B2 (ja) 結核の免疫治療および診断のための化合物およびそれらの使用方法
CA2759583C (fr) Vaccin contre la tuberculose tb pour prevenir une reactivation
US7037510B2 (en) Hybrids of M. tuberculosis antigens
AU723606B2 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
AU779495B2 (en) Tuberculosis vaccine and diagnostics based on the mycobacterium tuberculosis esat-6 gene family
US5985287A (en) Compounds and methods for treatment and diagnosis of mycobacterial infections
WO2005061534A2 (fr) Vaccins antituberculeux ameliores
US20040013685A1 (en) Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
CA2346218A1 (fr) Vaccin et diagnostic tb selon les antigenes de la cellule du bacille de koch
AU741016B2 (en) Compounds and methods for treatment and diagnosis of mycobacterial infections

Legal Events

Date Code Title Description
FZDE Discontinued